New paradigms of clinical trial design for genetic prion diseases by Aguzzi, Adriano & Frontzek, Karl








New paradigms of clinical trial design for genetic prion diseases
Aguzzi, Adriano ; Frontzek, Karl
DOI: https://doi.org/10.1016/s1474-4422(20)30029-6





Aguzzi, Adriano; Frontzek, Karl (2020). New paradigms of clinical trial design for genetic prion diseases.
Lancet Neurology, 19(4):284-285.
DOI: https://doi.org/10.1016/s1474-4422(20)30029-6
New paradigms of clinical trial design for genetic prion diseases 
 
 
Adriano Aguzzi, Karl Frontzek 
 
Institute of Neuropathology, University of Zurich, Rämistrasse 100, CH-8091 Zurich 
Corresponding author: adriano.aguzzi@usz.ch 
We declare no competing interests. 
 
 
Diagnosis of a genetic, incurable disease is devastating for the affected individuals and their 
families. In the case of genetic prion disease, a rare disease of the CNS caused by mutations 
of the human prion protein gene PRNP, mutation carriers usually do not exhibit symptoms until 
late adulthood. Genetic prion diseases comprise a relatively small fraction (10–15%) of all prion 
diseases, the most common being sporadic Creutzfeldt-Jakob Disease1. Since no therapy 
exists except palliation, individuals with a family history of genetic prion disease are facing the 
dilemmatic decision whether to undergo genetic testing.  
Due to the phenotypic variability of genetic prion diseases and the lack of biomarkers that 
predict clinical onset, sufficiently powered clinical trials would require several hundreds of 
individuals — an unrealistic scenario given the rarity of these diseases. Three unsuccessful 
randomised controlled trials were conducted in patients with human prion disease using the 
analgesic flupirtine, the antiprotozoal quinacrine, and the antibiotic doxycycline. In addition to 
the weak rationale for employing these drugs, participants were already symptomatic at the 
time of enrollment and most likely beyond any therapeutic windows1. In The Lancet Neurology, 
Sonia Vallabh and colleagues provide a roadmap for a therapeutic trial against genetic prion 
diseases using PRNP-targeting antisense oligonucleotides (ASOs)2. ASOs are short single-
stranded synthetic oligodeoxynucleotides that bind to pre-messenger ribonucleic acid (mRNA) 
by Watson-Crick pairing. The resulting RNA-DNA complexes are then degraded via RNases3. 
ASOs have gained attention as potential therapies for CNS diseases since the approval of 
nusinersen for the treatment of spinal muscular atrophy by the US Food and Drug 
administration (FDA) in 2016.  
A hallmark of prion diseases is the seeded aggregation of a partially protease-resistant isoform 
of the prion protein PrPSc onto the cellular isoform PrPC. Mice devoid of Prnp, the gene 
encoding PrPC, are resistant to prion diseases, and crucially hemizygosity for Prnp 
conspicuously prolongs the latency time of disease4. To lower PrPC levels in brains of PRNP 
mutation carriers, Vallabh and co-workers propose a prophylactic treatment regimen using 
ASOs against PRNP in the framework of an Accelerated Approval procedure by the FDA. 
Vallabh and colleagues had previously provided proof-of-concept evidence that 
prophylactically administered ASOs against Prnp reduce prion pathology, vacuolation, and 
PrPSc deposits of prion-infected mice, and most importantly extend their life-span5. In the trial 
laid out by Vallabh and co-workers, PrPC levels in CSF, which provide a robust surrogate 
marker for PrPC levels in brain, can be easily measured by conventional ELISA, thereby 
providing a means to monitor the pharmacodynamic on-target effectiveness of the therapy.  
Lowering PrPC levels in the brain reduces prion disease susceptibility, but this strategy is not 
without risks. Whereas certain phenotypes of Prnp knock-out mice were shown to be genetic 
artifacts, peripheral demyelinating polyneuropathy was a consistent feature due to the action 
of PrPC onto its receptor Adgrg66. Prnp heterozygous mice, however, did not show 
demyelination, suggesting that PrPC levels might not limit Schwann-cell health6.  
Which treatments may compete with ASOs for treatment of prion diseases? Anti-PrPC 
antibodies delay disease onset in animal experiments7, but the blood-brain barrier is still a 
formidable obstacle despite promising inroads8. As of October 2019, PRN100, a humanized 
monoclonal antibody against the C-terminal domain of PrPC, was given to six patients 
diagnosed with sporadic Creutzfeldt-Jakob Disease; the outcome is still undisclosed. 
Polythiophenes are anionic compounds that act as prion hyperstabilizers9. Although rational 
design of luminescent conjugated polymers, anti-prion compounds based on polythiophenes, 
prolonged survival of prion-infected mice9, a therapeutic window has not been established yet. 
Meanwhile, ASOs are increasingly successful in diseases as disparate as spinal muscular 
atrophy (nusinersen), Duchenne muscular dystrophy (eteplirsen), and familial 
hypercholesterolemia (mipomersen). 
Most individuals affected by genetic prion diseases are aware of their mutation years or even 
decades prior to symptom onset. This makes them ideally suited for the prophylactic trial 
proposed by Vallabh and co-workers. Likewise, carriers of autosomal-dominant mutations in 
the PSEN1 gene, manifesting as Alzheimer’s disease, are part of a preventive placebo-
controlled trial involving the anti-β-amyloid antibody crenezumab10. However, PSEN1 
mutations are more prevalent than PRNP mutations and have a more predictable clinical 
course10. 
Lastly, this trial is also personal: Sonia Vallabh, the first author of the paper, is a PRNP 
mutation carrier herself and has been at the forefront of innovative clinical trials in genetic prion 
disease. Those who have had the opportunity to experience Ms Vallabh’s courage and 
gallantry will most likely agree that this trial will bring a significant advance towards the therapy 
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